Substituted Aromatic Compounds for Fibrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrotic diseases such as pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, cardiac fibrosis, and macular degeneration lack effective and convenient therapeutic options, with existing medications often being toxic, having limited efficacy, or requiring invasive administration methods.
Innovation Solution
Development of novel substituted aromatic compounds that reduce collagen production and inhibit fibrotic processes, administered orally or topically, to treat and prevent fibrotic diseases by targeting key pathways involved in fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat fibrotic diseases, then some therapeutic effect is achieved, but toxicity and limited efficacy occur
Solution Approach 1:
The patent modifies the chemical structure of aromatic compounds by changing parameters such as substituent groups (R1-R6), chain lengths (m, n), and functional groups (Q) to optimize the balance between therapeutic efficacy and toxicity. This structural parameter optimization allows the compounds to maintain antifibrotic activity while reducing harmful effects compared to existing medications.
Solution Approach 2:
The patent develops composite aromatic compounds with multiple substituent groups and functional moieties that work synergistically to enhance therapeutic effect while reducing toxicity. The complex molecular structure incorporates multiple pharmacophores that target different aspects of fibrosis pathology, creating a more effective and safer therapeutic agent.
2Reliability
If existing treatments are administered, then some fibrotic disease symptoms are addressed, but invasive administration methods are required
Solution Approach 1:
The patent replaces invasive mechanical administration methods (such as injections or surgical interventions) with oral or topical administration routes. The chemically modified aromatic compounds are designed to be stable and bioavailable when administered through non-invasive routes, thereby improving patient compliance and ease of operation while maintaining treatment effectiveness.
3Ease of operation
If current therapies are used for fibrotic diseases, then treatment is provided, but safety concerns arise due to toxicity
Solution Approach 1:
The patent optimizes safety parameters by modifying molecular structure parameters including substituent types, chain lengths, and functional groups. These changes improve the therapeutic index by enhancing selective binding to fibrosis-related targets while reducing off-target effects and systemic toxicity, making the treatment safer and more accessible.
Solution Approach 2:
The aromatic compounds act as intermediary molecules that selectively interact with and modulate key pathways in fibrosis (such as TGF-β signaling, collagen synthesis pathways) without directly affecting healthy tissues. This intermediary action provides targeted therapy that spares normal cells from toxic effects.
Data Source
AI summary
The present invention relates to compounds of:or a pharmaceutically acceptable salt thereof, whereinA is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4;R1 is H, F or OH;R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4;R3 is H, F, OH or CH2Ph;R4 is H, F or OH;Q is1) (CH2)mC(O)OH wherein m is 1 or 2,2) CH(CH3)C(O)OH,3) C(CH3)2C(O)OH,4) CH(F)—C(O)OH,5) CF2—C(O)OH, or6) C(O)—C(O)OH;and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.